Loading...
XKRX
064550
Market cap105mUSD
Jul 10, Last price  
6,410.00KRW
1D
3.89%
1Q
-38.60%
Jan 2017
-13.03%
IPO
-49.53%
Name

BioneerCorp

Chart & Performance

D1W1MN
XKRX:064550 chart
P/E
P/S
0.50
EPS
Div Yield, %
Shrs. gr., 5y
0.99%
Rev. gr., 5y
9.79%
Revenues
330.11b
+12.29%
20,533,917,88023,904,100,69017,853,516,18020,833,715,30721,703,614,69923,267,735,47424,077,825,95636,292,397,000206,987,465,000223,743,694,000218,394,453,000263,236,802,635293,975,485,000330,110,658,000
Net income
-2.81b
L-86.33%
-8,022,353,080-7,152,484,830-13,559,179,820-5,372,140,420-14,418,909,089-9,941,285,943-8,818,353,336-7,826,654,00057,899,193,00027,159,524,00012,076,879,000-10,587,029,811-20,584,198,000-2,813,157,000
CFO
10.33b
P
-2,714,095,840-3,787,214,090-4,314,334,030407,678,862-2,511,535,212-3,902,011,230-8,113,572,202-5,589,453,00095,705,377,00053,174,659,0008,805,263,0004,135,856,000-13,476,386,00010,331,360,000
Dividend
Mar 15, 20220.285 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bioneer Corporation, established in 1992 and headquartered in Daejeon, South Korea, is a biotechnology company involved in diverse fields such as research products, molecular diagnostics, pharmaceuticals, and probiotics. For the biotechnology research market, Bioneer offers a wide array of consumables and reagents, including PCR and RT-PCR kits, real-time PCR solutions, RNA interference products, various chemicals, plastic laboratory essentials, and buffer solutions. The company also provides an extensive range of services like sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher services, electrophoresis, genome-wide functional analysis, and magnetic separation techniques. Additionally, Bioneer manufactures sophisticated instruments for conventional and real-time PCR, sample preparation, protein synthesis, centrifugation, vortex mixing, electrophoresis, spectrophotometry, and microbial culture. In molecular diagnostics, it supplies MDx technologies, human diagnostic kits, MDx extraction kits, and the necessary instrumentation. Furthermore, Bioneer develops specialized products for animal health and cutting-edge nano-biotechnology applications.
IPO date
Dec 29, 2005
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT